Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.71 |
| ▸ | NPC1 | O15118 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | STAT1 | P42224 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614565 | 0.91 | TSHR (0.68) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL4877547 | 0.83 | RAB9A (0.71) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2758613 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL6749406 | 0.83 | RAB9A (0.71) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2758639 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL10719050 | 0.83 | RAB9A (0.71) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL7695763 | 0.82 | ALOX15 (0.79) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL3025349 | 0.82 | ALOX15 (0.79) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL10983354 | 0.81 | ALOX15 (0.76) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7955987 | 0.79 | ALOX15 (0.73) | RAB9ANPC1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | RAB9A 4056/4885NPC1 1022/4885KDM4E 1784/4885 |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | RAB9A 3960/4885NPC1 2981/4885KDM4E 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.